Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02848911
Other study ID # AFM11-102
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date October 2016
Est. completion date April 2019

Study information

Verified date June 2019
Source Affimed GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to determine the maximum tolerated dose (MTD) in patients with acute lymphoblastic leukemia (ALL) and to determine the safety and tolerability of increasing doses and different infusion times of AFM11 infusion in patients with adult B-precursor ALL


Description:

Acute lymphoblastic leukemia (ALL) is an aggressive type of leukemia characterized by an overproduction of lymphoblasts or lymphocytes in the bone marrow and the peripheral blood; it is frequently accompanied by suppression of normal hematopoiesis. It can spread to the lymph nodes, spleen, liver, the central nervous system (CNS), and other organs (sanctuary sites). Without treatment, ALL usually progresses quickly.

B- and T-cell lymphoblastic leukemia cells express surface antigens that parallel their respective developmental lineages. Precursor B-cell ALL cells typically express CD10, CD19, and CD34 on their surface, along with nuclear terminal deoxynucleotide transferase. About 20% of adult ALL patients have a cytogenetic abnormality that is indistinguishable from the Philadelphia chromosome (Ph1, t(9;22)), according to the National Cancer Institute (NCI).

The rationale for the use of AFM11 is based on its ability to bind to both malignant cells via its anti-CD19 domain and to T-cells via its anti-CD3 domains. This results in the formation of the "immunological synapse" and the subsequent T-cell activation on leading to killing of malignant cells. AFM11 has 2 binding sites for CD19 and 2 for CD3, its molecular weight is ~ 105kDa compared to diabodies like blinatumomab with one binding site for each target and a much lower molecular weight ~ 55kDa. In addition, preclinical experiments have shown that AFM11 has about a 100 fold higher affinity to CD3 compared to diabodies and is inducing higher cytotoxicity in vitro in the presence of low effector:target cell ratios. These differences might allow for a shortening of the infusion times and potentially higher clinical efficacy compared to blinatumomab.


Recruitment information / eligibility

Status Terminated
Enrollment 17
Est. completion date April 2019
Est. primary completion date September 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patients with CD19+ B-precursor Philadelphia-chromosome negative ALL relapsed after at least induction and consolidation or having refractory disease and who are not candidates for bone marrow transplant (including both peripheral blood and hematopoietic stem cell transplant [HSCTs]) with a curative intent at time of screening

2. Patients with CD19+ Philadelphia-chromosome positive ALL who failed or were intolerant to therapy with at least 2 approved tyrosine kinase inhibitors

3. More than 5% blasts in bone marrow

4. In patients with high tumor burden (e.g., more than 50% blasts, or more than 15,000 blasts /µL blood, or elevated lactate dehydrogenase [LDH]) > 2 × upper limit of normal [ULN]), a pre treatment with 10 mg/m2 dexamethasone and 200 mg cyclophosphamide could be administered for up to 5 days.

5. Patients of both genders, age = 18

6. Homogenous CD19 expression on leukemic blasts must be confirmed by either:

1. Prior results from a CD19+ staining or flow cytometry at the most recent available diagnostic bone marrow biopsy or aspirate, or

2. Submission of a recent bone marrow biopsy for staining for CD19 positivity. The results of this testing need to be available prior to start of AFM11 treatment.

7. Eastern Cooperative Oncology Group performance status = 2

8. Life expectancy of at least 3 months

9. Ability to understand the patient information and informed consent form

10. Signed and dated written informed consent

Exclusion Criteria:

1. Autologous HSCT within 3 months prior to start of AFM11 treatment

2. Active acute or chronic graft-versus-host disease. All graft-versus-host disease medication should be omitted for at least 4 weeks prior to start of AFM11 treatment.

3. Allogeneic HSCT within 3 months prior to start of AFM11 treatment

4. Prior treatment with blinatumomab or any other CD19 targeting T-cell engager, including CD19 CAR-T cells

5. Treatment with donor-lymphocyte infusions within 4 weeks of start of AFM11 treatment or existing Graft versus Host Disease (GvHD)

6. Known or suspected central nervous system (CNS) involvement:

1. Evidence for presence of malignant disease, inflammatory lesions, and/or vasculitis on cerebral magnetic resonance imaging (MRI)

2. Infiltration of the cerebrospinal fluid by malignant B-cells, confirmed by lumbar puncture

7. History of or current relevant CNS pathology as epilepsy, seizure, paresis, aphasia, apoplexia, severe brain injuries, cerebellar disease, organic brain syndrome, psychosis

8. Cancer chemotherapy within 4 weeks prior to start of AFM11 treatment, or at least 4 times the respective half-lives, whichever is longer

9. Therapy with antibody, or antibody constructs within 4 weeks prior to the start of AFM11 treatment, or at least 4 half-lives, whichever is longer

10. Treatment with any investigational agent within 4 weeks prior to start of AFM11 treatment, or at least 4 times the respective half-life, whichever is longer

11. Contraindication for any of the concomitant medications

12. Abnormal renal or hepatic function as follows: aspartate aminotransferase (AST or SGOT) and/or alanine aminotransferase (ALT or SGPT) = 2.5 × ULN; total bilirubin = 1.5 × ULN; serum creatinine = 2 × ULN; creatinine clearance < 50 mL/minute

13. History of malignancy other than B-cell lymphoma or B-precursor ALL within 5 years prior to study entry, with the exception of basal cell carcinoma of the skin or carcinoma in situ of the cervix

14. Uncontrolled infections; known bacteremia

15. Any concurrent disease or medical condition that is deemed to interfere with the conduct of the study as judged by the Investigator

16. Clinically relevant coronary artery disease (New York Heart Association [NYHA] functional angina classification III/IV), congestive heart failure (NYHA III/IV), high risk of or known uncontrolled arrhythmia

17. Regular dose of corticosteroids during the 4 weeks prior to start of AFM11 treatment of this study or anticipated need of corticosteroids exceeding prednisone 20 mg/day or equivalent, or any other immunosuppressive therapy within 4 weeks prior to study entry. Exception is the pre treatment of rapidly progressing disease

18. Known infection with human immunodeficiency virus or chronic or acute infection with hepatitis B or hepatitis C virus

19. Pregnant or nursing women or women of childbearing potential not willing to use an effective form of contraception during participation in the study and at least 3 months thereafter. Male patients not willing to ensure that during the study and at least 3 months thereafter no fathering takes place. Effective methods of contraception include intrauterine device (IUD), combined (estrogen- and progesterone-containing) hormonal contraception (oral, vaginal ring or transdermal patch) with an ethinylestradiol dose of at least 30 µg, plus use of male condoms (preferably with spermicides), female condoms, a female diaphragm, or a cervical cap.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AFM11
Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 2 weeks

Locations

Country Name City State
Austria LKH-Universitätsklinikum Graz Graz
Austria Kepler Universitätsklinikum Linz Linz
Austria Uniklinikum Salzburg Salzburg
Czechia University Hospital Brno
Israel Rambam Medical Center Haifa
Israel Hadassah Medical Center Jerusalem
Israel Rabin Medical Center Petah-Tikva
Poland Independent Public Healthcare Municipal Hospital Chorzow
Poland University Hospital Krakow
Russian Federation Baranov Republican Hospital Petrozavodsk
Russian Federation Almazov NW Federal Medical Research Center St. Petersburg
Russian Federation First Pavlov State Medical University St. Petersburg

Sponsors (1)

Lead Sponsor Collaborator
Affimed GmbH

Countries where clinical trial is conducted

Austria,  Czechia,  Israel,  Poland,  Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with serious and non-serious adverse events as a measure of safety and tolerability of increasing doses and different infusion times of AFM11 Measure of occurence of adverse events (AEs), laboratory testing (chemistry and hematology), physical examination, vital signs, cardiac monitoring, and neurological assessments From first administration of continuous infusion over 2 weeks in step 1 (or 4 weeks in step 2) followed by 2 weeks of treatment break
Secondary Maximum Plasma Concentration of AFM11 (Cmax) The maximum observed concentration of AFM11 in plasma will be determined. Multiple time points during the 2 weeks of treatment in step 1 and 4 weeks of treatment in step 2
Secondary Area Under the Curve (AUC) The area under the concentration versus time curve from time zero to the sampling time will be determined. Prior to initial dose on Day 1 and at multiple time points during the 2 weeks of treatment in step 1 and 4 weeks of treatment in step 2
Secondary Clinical efficacy of AFM11 in ALL Measured by bone marrow assessment (complete response [CR], complete response with incomplete hematological recovery [CRh], and minimal residual disease [MRD]) Baseline and after treatment (week 3 in step 1 or week 4 in step 2)
Secondary Measurement of immunological markers Immunological markers like lymphocytes and cytokine levels in serum will be measured at different time points during the 4 weeks of treatment and 30 days thereafter to assess the level of activity resulting from administration of AFM11. Prior to initial dose on Day 1 and at multiple time points during the 2 weeks of treatment in Step 1 and 4 weeks of treatment in Step 2
See also
  Status Clinical Trial Phase
Withdrawn NCT03605589 - Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma Phase 1
Enrolling by invitation NCT02473757 - Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Recruiting NCT04649983 - CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma Phase 1/Phase 2
Recruiting NCT03614858 - CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. Phase 1/Phase 2
Terminated NCT02518750 - Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Phase 2
Enrolling by invitation NCT03229200 - Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. Phase 4
Recruiting NCT04439721 - γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse Early Phase 1
Not yet recruiting NCT03599375 - Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia Phase 1
Recruiting NCT02813837 - Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies N/A
Recruiting NCT04271410 - CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03598179 - XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects Phase 2
Recruiting NCT05254743 - A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Phase 3
Recruiting NCT05010564 - Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL) Phase 1
Recruiting NCT03564977 - CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation N/A
Recruiting NCT05362773 - A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies Phase 1
Recruiting NCT02672501 - A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia Phase 1/Phase 2
Not yet recruiting NCT06209671 - INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia Phase 1
Recruiting NCT03564470 - Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL Phase 2/Phase 3
Recruiting NCT04271800 - Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma Phase 1/Phase 2
Completed NCT01087294 - Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation Phase 1